These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14519091)

  • 1. Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.
    Sarabu R
    Expert Opin Investig Drugs; 2003 Oct; 12(10):1721-6. PubMed ID: 14519091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and investigational antiobesity agents and obesity therapeutic treatment targets.
    Bays HE
    Obes Res; 2004 Aug; 12(8):1197-211. PubMed ID: 15340100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
    Xu J
    IDrugs; 2004 Sep; 7(9):839-40. PubMed ID: 15470600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
    Xu J
    IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
    Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
    Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the glucagon receptor family for diabetes and obesity therapy.
    Cho YM; Merchant CE; Kieffer TJ
    Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current therapies and emerging targets for the treatment of diabetes.
    Wagman AS; Nuss JM
    Curr Pharm Des; 2001 Apr; 7(6):417-50. PubMed ID: 11281851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-Domínguez A; Comuzzie AG
    Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
    Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T
    Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications.
    Chen X; Hussain S; Parveen S; Zhang S; Yang Y; Zhu C
    Curr Med Chem; 2012; 19(21):3578-604. PubMed ID: 22664250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
    Chen D; Liao J; Li N; Zhou C; Liu Q; Wang G; Zhang R; Zhang S; Lin L; Chen K; Xie X; Nan F; Young AA; Wang MW
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):943-8. PubMed ID: 17213311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
    Holz GG; Chepurny OG
    Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.